Latest news and press releases about Co-Diagnostics, Inc. (CODX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting.
Price
| Price | $0.94 |
| Market Cap | $1M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.30 |
| EV / EBITDA | 0.01 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -210.99% |
| Return on Invested Capital | -200.40% |
| Return on Assets | -283.63% |
| Gross Margin | 8.07% |
| Operating Margin | -4170.14% |
| Net Margin | -6523.04% |
Related companies: ADGM · AEMD · ALUR · DWTX · NVNO · PRPH · SINT
Explore sector: Healthcare · Biotechnology
More sections of CODX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks